Barclays PLC Grows Stake in Ocugen, Inc. (NASDAQ:OCGN)

Barclays PLC increased its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN) by 104.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 581,087 shares of the company’s stock after purchasing an additional 296,654 shares during the quarter. Barclays PLC’s holdings in Ocugen were worth $577,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in OCGN. Bank of New York Mellon Corp lifted its position in shares of Ocugen by 2,760.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 751,819 shares of the company’s stock worth $1,165,000 after buying an additional 725,536 shares during the last quarter. State Street Corp raised its stake in Ocugen by 7.1% during the 3rd quarter. State Street Corp now owns 15,824,517 shares of the company’s stock worth $15,701,000 after acquiring an additional 1,047,896 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in Ocugen in the second quarter valued at $67,000. Profund Advisors LLC acquired a new position in Ocugen in the second quarter valued at $227,000. Finally, XTX Topco Ltd purchased a new position in shares of Ocugen during the third quarter worth about $233,000. 10.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OCGN has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research report on Monday, November 11th. Maxim Group assumed coverage on Ocugen in a report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Ocugen in a report on Monday, November 18th.

Ocugen Stock Performance

NASDAQ OCGN opened at $0.81 on Thursday. The firm has a market cap of $234.51 million, a P/E ratio of -4.47 and a beta of 3.82. Ocugen, Inc. has a 52-week low of $0.49 and a 52-week high of $2.11. The business’s 50-day moving average price is $0.90 and its 200 day moving average price is $1.16. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.